logo-loader

Geron awarded three patents for telomerase inhibitor

Last updated: 10:53 13 Jul 2016 EDT, First published: 05:53 13 Jul 2016 EDT

picture of patent document
The three US patents related to the company’s telomerase inhibitor, imetelstat

Geron Corporation (NASDAQ:GERN) has received three US patents related to the company’s telomerase inhibitor, imetelstat.

The first patent covers its use alleviating at least one symptom of myelofibrosis or myelodysplastic syndromes, including chronic myelomonocytic leukemia.

The other two patents relate to the use of imetelstat to inhibit cancer cell proliferation, as well as methods for using imetelstat to treat cancer.

Geron has licensed its portfolio of patents related to imetelstat to Janssen Biotech, which is conducting two clinical trials. 

Coniagas Battery Metals secures new key ground with focus on...

Coniagas Battery Metals (TSX-V:COS) CEO Frank Basa joined Steve Darling from Proactive to announce the company's strategic acquisition of key ground near SOQUEM’s Cardinal Property, located 80 km southeast of Chibougamau, Quebec. This acquisition underscores Coniagas’ commitment to capitalizing...

51 minutes ago